Akcea Therapeutics, Inc. (NASDAQ:AKCA) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,530,743 shares, an increase of 168.0% from the August 31st total of 571,132 shares. Based on an average daily trading volume, of 753,963 shares, the short-interest ratio is presently 2.0 days. Approximately 10.3% of the company’s stock are sold short.

Akcea Therapeutics (AKCA) opened at 28.03 on Wednesday. The stock’s 50 day moving average is $22.14 and its 200 day moving average is $17.15. The stock’s market capitalization is $1.80 billion. Akcea Therapeutics has a 12-month low of $8.10 and a 12-month high of $31.23.

A number of analysts have recently issued reports on AKCA shares. BMO Capital Markets began coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set an “outperform” rating and a $27.00 price objective on the stock. Cowen and Company started coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Akcea Therapeutics in a research note on Tuesday, August 8th. They issued a “buy” rating and a $19.00 price objective on the stock.

In other Akcea Therapeutics news, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the stock in a transaction dated Wednesday, July 19th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $25,000,000.00. Following the completion of the acquisition, the insider now owns 28,884,540 shares of the company’s stock, valued at approximately $231,076,320. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/akcea-therapeutics-inc-akca-sees-large-increase-in-short-interest/1606373.html.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.